Dostarlimab granted FDA accelerated approval in recurrent or advanced dMMR endometrial cancer

Written by Rachel Jenkins, Future Science Group


>>>Free access to Future Oncology’s ‘Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer’ Drug Evaluation article when you become a member of Oncology Central<<< The US FDA has recently approved GSK’s JEMPERLI – dostarlimab-gxly – for women with mismatch repair-deficient (dMMR) endometrial cancer. Dostarlimab is a PD-1-blocking antibody that is indicated for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum-containing regimen. Dr Hal Barron, Chief Scientific Officer and President R&D at GSK commented: “Unfortunately, as many as 60,000 women are diagnosed with endometrial...

To view this content, please register now for access

It's completely free